Transplanting insulin-producing stem cells for treating Type 1 Diabetes
Autologous Insulin Producing Mesenchymal Stem Cell Transplantation in Youth With Type 1 Diabetes
PHASE2; PHASE3 · Ain Shams University · NCT06951074
This study is testing whether transplanting insulin-producing stem cells from fat can help people with Type 1 Diabetes better control their blood sugar levels.
Quick facts
| Phase | PHASE2; PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 15 Years to 18 Years |
| Sex | All |
| Sponsor | Ain Shams University (other) |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06951074 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of autologous insulin-producing mesenchymal stem cells derived from adipose tissue to treat patients with Type 1 Diabetes. The study aims to differentiate these stem cells into insulin-producing cells and assess their ability to regulate blood sugar levels post-transplant. By utilizing a multistep differentiation technique, the researchers hope to restore pancreatic function and improve glycemic control in participants. The trial will evaluate both in vitro and in vivo insulin production following the infusion of these stem cells.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with Type 1 Diabetes who do not have other autoimmune diseases or chronic conditions.
Not a fit: Patients with other autoimmune diseases or those experiencing micro or macro vascular complications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve glycemic control and reduce the dependency on insulin therapy for patients with Type 1 Diabetes.
How similar studies have performed: Other studies have shown promise in using stem cell therapies for Type 1 Diabetes, but this specific approach using adipose-derived mesenchymal stem cells is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 1 diabetes Exclusion Criteria: * patients with other autoimmune diseases * patients with micro or macro vascular complications * patients with other chronic diseases
Where this trial is running
Cairo
- Children Hospital Eldemerdash — Cairo, Egypt (RECRUITING)
Study contacts
- Principal investigator: Rasha S Elmetwally, A. Prof — Assistant professor of Pediatrics, Faculty of Medicine, Ain Shams University
- Study coordinator: Rasha S Elmetwally, MD
- Email: dr.rashaeladawy@med.asu.edu.eg
- Phone: 20201092143033
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Stem Cells, Type 1 Diabetes